{"id":"kineret","rwe":[{"pmid":"41739653","year":"2026","title":"Therapeutic Approaches to Treat SARS-CoV-2.","finding":"","journal":"ChemMedChem","studyType":"Clinical Study"},{"pmid":"30000931","year":"2006","title":"Anakinra.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41166331","year":"2025","title":"Kineret: Israel's Largest Hospital Network Transformed into the OMOP common data model for collaborative research.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"39557607","year":"2025","title":"Interleukin-1 type 1 receptor blockade attenuates the exaggerated exercise pressor reflex in male UC Davis type 2 diabetic mellitus rats.","finding":"","journal":"The Journal of physiology","studyType":"Clinical Study"},{"pmid":"39355382","year":"2024","title":"Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis.","finding":"","journal":"International journal of women's health","studyType":"Clinical Study"}],"tags":[{"label":"Interleukin-1 Receptor Antagonist","category":"class"},{"label":"Biologic","category":"modality"},{"label":"Interleukin-1 receptor, type I","category":"target"},{"label":"IL1R1","category":"gene"},{"label":"IL1RAP","category":"gene"},{"label":"L04AC03","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"COVID19 pneumonia requiring supplemental oxygen","category":"indication"},{"label":"Chronic infantile neurological, cutaneous and articular syndrome","category":"indication"},{"label":"Cryopyrin associated periodic syndrome","category":"indication"},{"label":"Familial Mediterranean fever","category":"indication"},{"label":"Rheumatoid arthritis","category":"indication"},{"label":"Still's disease","category":"indication"},{"label":"Biovitrum Ab","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Antirheumatic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1253.664,"date":"","count":2426,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 2,426 times (LLR=1254)"},{"llr":955.425,"date":"","count":260,"signal":"Apparent death","source":"DrugCentral FAERS","actionTaken":"Reported 260 times (LLR=955)"},{"llr":822.479,"date":"","count":1780,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 1,780 times (LLR=822)"},{"llr":613.24,"date":"","count":364,"signal":"Red blood cell sedimentation rate increased","source":"DrugCentral FAERS","actionTaken":"Reported 364 times (LLR=613)"},{"llr":608.465,"date":"","count":843,"signal":"Joint swelling","source":"DrugCentral FAERS","actionTaken":"Reported 843 times (LLR=608)"},{"llr":596.628,"date":"","count":266,"signal":"Red blood cell sedimentation rate abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 266 times (LLR=597)"},{"llr":552.853,"date":"","count":255,"signal":"Haemophagocytic lymphohistiocytosis","source":"DrugCentral FAERS","actionTaken":"Reported 255 times (LLR=553)"},{"llr":517.793,"date":"","count":143,"signal":"Body height below normal","source":"DrugCentral FAERS","actionTaken":"Reported 143 times (LLR=518)"},{"llr":507.277,"date":"","count":132,"signal":"Human antichimeric antibody positive","source":"DrugCentral FAERS","actionTaken":"Reported 132 times (LLR=507)"},{"llr":488.281,"date":"","count":207,"signal":"Polyarthritis","source":"DrugCentral FAERS","actionTaken":"Reported 207 times (LLR=488)"},{"llr":485.135,"date":"","count":212,"signal":"Bone density decreased","source":"DrugCentral FAERS","actionTaken":"Reported 212 times (LLR=485)"},{"llr":470.947,"date":"","count":735,"signal":"Drug intolerance","source":"DrugCentral FAERS","actionTaken":"Reported 735 times (LLR=471)"},{"llr":432,"date":"","count":577,"signal":"Contraindicated product administered","source":"DrugCentral FAERS","actionTaken":"Reported 577 times (LLR=432)"},{"llr":430.15,"date":"","count":443,"signal":"Mobility decreased","source":"DrugCentral FAERS","actionTaken":"Reported 443 times (LLR=430)"},{"llr":394.487,"date":"","count":173,"signal":"Deformity","source":"DrugCentral FAERS","actionTaken":"Reported 173 times (LLR=394)"}],"commonSideEffects":[{"effect":"Injection site reaction","drugRate":"71%","severity":"common","organSystem":""},{"effect":"Infection","drugRate":"39%","severity":"common","organSystem":""},{"effect":"Worsening of rheumatoid arthritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Sinusitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Flu-like symptoms","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Influenza-like illness","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastroenteritis","drugRate":"","severity":"common","organSystem":""}],"specialPopulations":{"Pregnancy":"Available data from retrospective studies and case reports on KINERET use in pregnant women are insufficient to identify drug associated risk of major birth defects, miscarriage, or maternal and fetal adverse events. There are risks to the mother and fetus associated with active rheumatoid arthritis or Cryopyrin-Associated Periodic Syndromes (CAPS). In animal reproduction studies, subcutaneous administration of anakinra to pregnant rats and rabbits during organogenesis demonstrated no evidence of fetal harm at doses up to 25 times the maximum recommended human dose","Geriatric use":"Because there is higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. No differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"KINERET is indicated for use in pediatric patients with NOMID and DIRA. The NOMID study included 36 pediatric patients: 13 below years, 18 between and 11 years, and between 12 and 17 years of age. subcutaneous KINERET starting dose of 1-2 mg/kg/day was administered in all age groups. An average maintenance dose of 3-4 mg/kg/day was adequate to maintain clinical response throughout the study irrespective of age but higher dose was, on occasion, required in severely affected patients.","Renal impairment":"This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function."},"seriousAdverseEvents":[{"effect":"Serious infection","drugRate":"3%","severity":"serious"},{"effect":"Serious infection in asthma patients","drugRate":"4.5%","severity":"serious"},{"effect":"Cellulitis","drugRate":"","severity":"serious"},{"effect":"Pneumonia","drugRate":"","severity":"serious"},{"effect":"Bone and joint infections","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["IL-1 receptor inhibitor","Anakinra","anakinra","interleukin-1 receptor antagonist"],"company":"Biovitrum Ab","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Kineret","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:43:07.445021+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:12.994211+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:43:07.517016+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kineret","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:13.341974+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:14.480665+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201570/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:14.134204+00:00"}},"allNames":"anakinra","offLabel":[],"synonyms":["anakinra","kineret"],"timeline":[{"date":"2001-11-14","type":"positive","source":"DrugCentral","milestone":"FDA approval (Biovitrum Ab)"},{"date":"2002-03-08","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"brandName":"Anakinra","ecosystem":[{"indication":"COVID19 pneumonia requiring supplemental oxygen","otherDrugs":[],"globalPrevalence":null},{"indication":"Chronic infantile neurological, cutaneous and articular syndrome","otherDrugs":[],"globalPrevalence":null},{"indication":"Cryopyrin associated periodic syndrome","otherDrugs":[{"name":"canakinumab","slug":"canakinumab","company":"Novartis Pharms"},{"name":"rilonacept","slug":"rilonacept","company":"Regeneron Pharmaceuticals"}],"globalPrevalence":8800},{"indication":"Familial Mediterranean fever","otherDrugs":[{"name":"canakinumab","slug":"canakinumab","company":"Novartis Pharms"},{"name":"colchicine","slug":"colchicine","company":"Merck"}],"globalPrevalence":2000000000},{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000},{"indication":"Still's disease","otherDrugs":[{"name":"tocilizumab","slug":"tocilizumab","company":"Genentech"}],"globalPrevalence":null}],"mechanism":{"target":"Interleukin-1 receptor, type I","novelty":"Follow-on","targets":[{"gene":"IL1R1","source":"DrugCentral","target":"Interleukin-1 receptor, type I","protein":"Interleukin-1 receptor type 1"},{"gene":"IL1RAP","source":"DrugCentral","target":"Interleukin-1 receptor, type I","protein":"Interleukin-1 receptor accessory protein"}],"moaClass":"Interleukin 1 Receptor Antagonists","modality":"Biologic","drugClass":"Interleukin-1 Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Anakinra specifically binds to the interleukin-1 receptor, type I, with high affinity, thereby inhibiting the binding of interleukin-1 to its receptor and subsequent activation of downstream signaling pathways that promote inflammation."},"commercial":{"launchDate":"2001","_launchSource":"DrugCentral (FDA 2001-11-14, BIOVITRUM AB)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5017","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Kineret","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kineret","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:47:05.983178","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:15.786042+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"daclizumab","drugSlug":"daclizumab","fdaApproval":"1997-12-10","relationship":"same-class"},{"drugName":"basiliximab","drugSlug":"basiliximab","fdaApproval":"1998-05-12","relationship":"same-class"},{"drugName":"rilonacept","drugSlug":"rilonacept","fdaApproval":"2008-02-27","relationship":"same-class"},{"drugName":"ustekinumab","drugSlug":"ustekinumab","fdaApproval":"2009-09-25","relationship":"same-class"},{"drugName":"tocilizumab","drugSlug":"tocilizumab","fdaApproval":"2010-01-08","relationship":"same-class"},{"drugName":"canakinumab","drugSlug":"canakinumab","fdaApproval":"2009-06-17","relationship":"same-class"},{"drugName":"secukinumab","drugSlug":"secukinumab","fdaApproval":"2015-01-21","relationship":"same-class"},{"drugName":"siltuximab","drugSlug":"siltuximab","fdaApproval":"2014-04-23","relationship":"same-class"},{"drugName":"brodalumab","drugSlug":"brodalumab","fdaApproval":"2017-02-15","relationship":"same-class"},{"drugName":"ixekizumab","drugSlug":"ixekizumab","fdaApproval":"2016-03-22","relationship":"same-class"},{"drugName":"sarilumab","drugSlug":"sarilumab","fdaApproval":"2017-05-22","relationship":"same-class"},{"drugName":"guselkumab","drugSlug":"guselkumab","fdaApproval":"2017-07-13","relationship":"same-class"},{"drugName":"tildrakizumab","drugSlug":"tildrakizumab","fdaApproval":"2018-03-20","relationship":"same-class"},{"drugName":"risankizumab","drugSlug":"risankizumab","fdaApproval":"2019-04-23","relationship":"same-class"},{"drugName":"satralizumab","drugSlug":"satralizumab","fdaApproval":"2020-08-14","relationship":"same-class"},{"drugName":"spesolimab","drugSlug":"spesolimab","fdaApproval":"2022-09-01","relationship":"same-class"}],"genericName":"kineret","indications":{"approved":[{"name":"COVID19 pneumonia requiring supplemental oxygen","source":"DrugCentral","snomedId":882785000000000000,"regulator":"FDA","eligibility":{"specific condition":"COVID19 pneumonia requiring supplemental oxygen"}},{"name":"Chronic infantile neurological, cutaneous and articular syndrome","source":"DrugCentral","snomedId":239826001,"regulator":"FDA","eligibility":{"specific condition":"Chronic infantile neurological, cutaneous and articular syndrome"}},{"name":"Cryopyrin associated periodic syndrome","source":"DrugCentral","snomedId":430079001,"regulator":"FDA","eligibility":{"specific condition":"Cryopyrin associated periodic syndrome"},"prevalenceClass":"1-9 / 1 000 000","globalPrevalence":8800,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet ([EXPERT]_17162528[PMID])"},{"name":"Familial Mediterranean fever","source":"DrugCentral","snomedId":12579009,"regulator":"FDA","eligibility":{"specific condition":"Familial Mediterranean fever"},"usPrevalence":null,"globalPrevalence":2000000000,"prevalenceMethod":"curated","prevalenceSource":"Common symptom, not a disease"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Still's disease","source":"DrugCentral","snomedId":239920006,"regulator":"FDA","eligibility":{"specific condition":"Still's disease"}}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"daclizumab","brandName":"daclizumab","genericName":"daclizumab","approvalYear":"1997","relationship":"same-class"},{"drugId":"basiliximab","brandName":"basiliximab","genericName":"basiliximab","approvalYear":"1998","relationship":"same-class"},{"drugId":"rilonacept","brandName":"rilonacept","genericName":"rilonacept","approvalYear":"2008","relationship":"same-class"},{"drugId":"ustekinumab","brandName":"ustekinumab","genericName":"ustekinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"tocilizumab","brandName":"tocilizumab","genericName":"tocilizumab","approvalYear":"2010","relationship":"same-class"},{"drugId":"canakinumab","brandName":"canakinumab","genericName":"canakinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"secukinumab","brandName":"secukinumab","genericName":"secukinumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"siltuximab","brandName":"siltuximab","genericName":"siltuximab","approvalYear":"2014","relationship":"same-class"},{"drugId":"brodalumab","brandName":"brodalumab","genericName":"brodalumab","approvalYear":"2017","relationship":"same-class"},{"drugId":"ixekizumab","brandName":"ixekizumab","genericName":"ixekizumab","approvalYear":"2016","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05267821","phase":"PHASE2,PHASE3","title":"Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-06-14","conditions":["Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)"],"enrollment":500,"completionDate":"2028-08-31"},{"nctId":"NCT06710197","phase":"PHASE2","title":"IL-1 Inhibition in Early TNBC","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2025-03-05","conditions":["Early Stage Triple Negative ER Low Breast Cancer"],"enrollment":0,"completionDate":"2026-02-12"},{"nctId":"NCT06724562","phase":"","title":"IL1 Inhibition in FOP","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-04-01","conditions":["Fibrodysplasia Ossificans Progressiva (FOP)"],"enrollment":11,"completionDate":"2027-03"},{"nctId":"NCT04205838","phase":"PHASE2","title":"Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-03-04","conditions":["Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma","Progressive Disease","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":23,"completionDate":"2026-02-19"},{"nctId":"NCT04747847","phase":"EARLY_PHASE1","title":"Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-06-22","conditions":["Kawasaki Disease"],"enrollment":5,"completionDate":"2022-08-17"},{"nctId":"NCT07423975","phase":"PHASE2","title":"Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-03-01","conditions":["Stroke Acute","Endovascular Treatment"],"enrollment":159,"completionDate":"2026-12-31"},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":["Postprandial Hypoglycemia"],"enrollment":0,"completionDate":"2026-05-01"},{"nctId":"NCT00339157","phase":"PHASE2,PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":["Systemic-Onset Juvenile Idiopathic Arthritis"],"enrollment":24,"completionDate":"2008-06-10"},{"nctId":"NCT02021422","phase":"PHASE1","title":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2013-12","conditions":["Pancreas Cancer"],"enrollment":13,"completionDate":"2021-06"},{"nctId":"NCT06974877","phase":"PHASE1","title":"Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":["Cryopyrin-Associated Periodic Syndromes","Amyloidosis"],"enrollment":30,"completionDate":"2032-01-31"},{"nctId":"NCT07410312","phase":"EARLY_PHASE1","title":"BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-02-01","conditions":["Lung Transplant Recipient"],"enrollment":20,"completionDate":"2027-12"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT04844814","phase":"PHASE2","title":"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation","status":"SUSPENDED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-02","conditions":["Gout","Chronic Kidney Disease","Renal Transplantation"],"enrollment":204,"completionDate":"2026-08-31"},{"nctId":"NCT07371689","phase":"PHASE3","title":"ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02","conditions":["PEDIATRIC ACUTE MYOCARDITIS"],"enrollment":110,"completionDate":"2029-12"},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":["Sepsis"],"enrollment":2000,"completionDate":"2031-05-01"},{"nctId":"NCT03968913","phase":"EARLY_PHASE1","title":"Biologic Therapy to Prevent Osteoarthritis After ACL Injury","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2021-09-15","conditions":["Anterior Cruciate Ligament Injuries"],"enrollment":32,"completionDate":"2027-01-30"},{"nctId":"NCT05177822","phase":"PHASE2","title":"Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2022-05-24","conditions":["Heart Failure"],"enrollment":84,"completionDate":"2027-12-30"},{"nctId":"NCT05926505","phase":"PHASE2,PHASE3","title":"Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2023-09-06","conditions":["Post-Acute COVID-19 Syndrome","Post-Acute COVID-19","Long COVID"],"enrollment":182,"completionDate":"2028-03"},{"nctId":"NCT05611710","phase":"PHASE2","title":"Anakinra in Dengue With Hyperinflammation ( AnaDen )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2023-01-02","conditions":["Dengue","Dengue With Warning Signs","Severe Dengue","Anakinra","Immuno-modulation","Anti-inflammatory Agents","Macrophage Activation Syndrome","Hyperinflammatory Syndrome","Cytokine Storm"],"enrollment":160,"completionDate":"2027-12-31"},{"nctId":"NCT05013450","phase":"PHASE1,PHASE2","title":"Dupilumab_Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2021-09-10","conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":33,"completionDate":"2025-12-09"},{"nctId":"NCT07281027","phase":"PHASE3","title":"COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03-01","conditions":["New Onset Refractory Status Epilepticus","New-Onset Refractory Status Epilepticus","Febrile Infection-Related Epilepsy Syndrome (FIRES)"],"enrollment":438,"completionDate":"2030-09-30"},{"nctId":"NCT07254000","phase":"PHASE2","title":"Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants","status":"RECRUITING","sponsor":"Monash Medical Centre","startDate":"2025-06-27","conditions":["Premature Infants","Very Premature Infants","Inflammation"],"enrollment":24,"completionDate":"2026-12"},{"nctId":"NCT04150913","phase":"PHASE2","title":"A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity","status":"COMPLETED","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2020-10-01","conditions":["Non Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Relapsed Non Hodgkin Lymphoma","Neurotoxicity","Neurotoxicity Syndromes","Cytokine Release Syndrome"],"enrollment":15,"completionDate":"2024-10-31"},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":["Inflammatory Disease","Autoimmune Diseases"],"enrollment":32,"completionDate":"2025-11"},{"nctId":"NCT05305014","phase":"","title":"Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-04-01","conditions":["Conversion Disorder"],"enrollment":20,"completionDate":"2022-04-15"},{"nctId":"NCT06062966","phase":"PHASE1","title":"The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2024-02-05","conditions":["Heart Failure"],"enrollment":20,"completionDate":"2026-06"},{"nctId":"NCT04926467","phase":"PHASE2","title":"Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2021-07-23","conditions":["Pancreatic Adenocarcinoma"],"enrollment":24,"completionDate":"2027-06"},{"nctId":"NCT04148430","phase":"PHASE2","title":"A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-10-30","conditions":["B Cell ALL","B-Cell Lymphoma","B-cell Non Hodgkin Lymphoma"],"enrollment":62,"completionDate":"2026-10"},{"nctId":"NCT04898231","phase":"PHASE2,PHASE3","title":"MIS-C Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-22","conditions":["Multisystem Inflammatory Syndrome-Children"],"enrollment":73,"completionDate":"2024-04-25"},{"nctId":"NCT04359784","phase":"PHASE2","title":"Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-12-27","conditions":["B-Cell Non-Hodgkin Lymphoma"],"enrollment":27,"completionDate":"2024-12-23"},{"nctId":"NCT07191444","phase":"","title":"A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-18","conditions":["Still's Disease, Adult-Onset"],"enrollment":20,"completionDate":"2027-07-31"},{"nctId":"NCT02929251","phase":"PHASE2","title":"Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-29","conditions":["Uveitis","Biotherapy"],"enrollment":112,"completionDate":"2022-01-29"},{"nctId":"NCT06418295","phase":"","title":"Cytokine Alterations and Chronic Post-Surgical Pain","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2026-01-01","conditions":["Chronic Post Operative Pain"],"enrollment":60,"completionDate":"2028-12-31"},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":["Rheumatic Disease"],"enrollment":80,"completionDate":"2027-09"},{"nctId":"NCT06001645","phase":"","title":"Laboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)","status":"RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2023-11-27","conditions":["Acute Respiratory Distress Syndrome","Barotrauma"],"enrollment":110,"completionDate":"2027-07"},{"nctId":"NCT04017936","phase":"PHASE2","title":"Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2020-10-23","conditions":["Cardiac Sarcoidosis"],"enrollment":17,"completionDate":"2024-06-30"},{"nctId":"NCT06757348","phase":"","title":"Fatty Liver and Pancreatic Steatosis","status":"NOT_YET_RECRUITING","sponsor":"Maria Marta Piskorz","startDate":"2025-09-01","conditions":["Exocrine Pancreatic Insufficiency","Fatty Liver, Nonalcoholic","Pancreatic Steatosis"],"enrollment":61,"completionDate":"2026-03-01"},{"nctId":"NCT03797001","phase":"PHASE2","title":"Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2019-01-04","conditions":["Heart Failure, Systolic","Inflammation"],"enrollment":102,"completionDate":"2024-07-22"},{"nctId":"NCT06336733","phase":"PHASE3","title":"Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-04","conditions":["FMF"],"enrollment":50,"completionDate":"2026-12-04"},{"nctId":"NCT06666335","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF","status":"NOT_YET_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-09-01","conditions":["Familial Mediterranean Fever (FMF )"],"enrollment":3,"completionDate":"2027-11-30"},{"nctId":"NCT06703216","phase":"PHASE1,PHASE2","title":"Pre-emptive Anakinra for Cytokine Event Reduction","status":"NOT_YET_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2025-08","conditions":["B-Acute Lymphoblastic Leukemia","CAR-T Cell Therapy","Cytokine Release Syndrome","Immune Effector Cell Associated Neurotoxicity Syndrome","Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome"],"enrollment":24,"completionDate":"2030-02-28"},{"nctId":"NCT04341584","phase":"PHASE2","title":"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-08","conditions":["Corona Virus Infection"],"enrollment":161,"completionDate":"2020-07-25"},{"nctId":"NCT03587701","phase":"PHASE2","title":"Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2019-01-03","conditions":["Autoimmune Inner Ear Disease","Meniere's Disease"],"enrollment":57,"completionDate":"2025-12-31"},{"nctId":"NCT05498467","phase":"PHASE3","title":"The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis","status":"COMPLETED","sponsor":"Herlev and Gentofte Hospital","startDate":"2022-10-11","conditions":["Allergic Contact Dermatitis"],"enrollment":20,"completionDate":"2024-08-01"},{"nctId":"NCT06624436","phase":"PHASE4","title":"Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-10-24","conditions":["Sepsis","Neuroinflammatory Response","Immunosuppresion","Endotoxemia","Anakinra","Dexamethasone","Tocilizumab"],"enrollment":52,"completionDate":"2025-12"},{"nctId":"NCT03925194","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF","status":"RECRUITING","sponsor":"Heidelberg University","startDate":"2022-12-01","conditions":["Cystic Fibrosis, 10011762"],"enrollment":52,"completionDate":"2026-12-01"},{"nctId":"NCT04990232","phase":"PHASE2","title":"Personalized Immunotherapy in Sepsis","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-07-29","conditions":["Sepsis"],"enrollment":280,"completionDate":"2024-04-27"},{"nctId":"NCT04119687","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2020-03-02","conditions":["Osteoarthritis, Knee"],"enrollment":72,"completionDate":"2026-11-28"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT05814159","phase":"PHASE3","title":"A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2022-08-24","conditions":["Still's Disease, Juvenile Onset","Still's Disease, Adult-Onset"],"enrollment":15,"completionDate":"2026-06-24"},{"nctId":"NCT04942626","phase":"PHASE1","title":"Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients","status":"COMPLETED","sponsor":"Goethe University","startDate":"2021-08-20","conditions":["Rectal Cancer"],"enrollment":12,"completionDate":"2024-12-31"},{"nctId":"NCT04826588","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2021-05-23","conditions":["Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)"],"enrollment":76,"completionDate":"2022-11-20"},{"nctId":"NCT04072822","phase":"PHASE2","title":"Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-07-10","conditions":["Alcoholic Hepatitis"],"enrollment":147,"completionDate":"2022-08-12"},{"nctId":"NCT02278562","phase":"PHASE2","title":"Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-22","conditions":["ESRD"],"enrollment":33,"completionDate":"2017-03-01"},{"nctId":"NCT04227769","phase":"PHASE2","title":"IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-01-13","conditions":["Diabetes Mellitus Type 2 in Obese","Inflammation","Metabolic Disease","Glucose Metabolism Disorders (Including Diabetes Mellitus)"],"enrollment":18,"completionDate":"2024-05-28"},{"nctId":"NCT05854251","phase":"PHASE2","title":"Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-06-15","conditions":["Hyperinsulinemia","PreDiabetes"],"enrollment":20,"completionDate":"2024-05-17"},{"nctId":"NCT04432506","phase":"PHASE2","title":"Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-27","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":22,"completionDate":"2024-05-28"},{"nctId":"NCT04025554","phase":"PHASE1,PHASE2","title":"Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2019-10-25","conditions":["Multiple Sclerosis"],"enrollment":8,"completionDate":"2023-10-24"},{"nctId":"NCT06697431","phase":"PHASE4","title":"Non Inferiority KawasakI Trial With Anakinra","status":"NOT_YET_RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-04-01","conditions":["Kawasaki Disease","Anakinra"],"enrollment":38,"completionDate":"2027-04-01"},{"nctId":"NCT04099901","phase":"PHASE2","title":"Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-11-04","conditions":["Multiple Myeloma"],"enrollment":88,"completionDate":"2024-02-26"},{"nctId":"NCT03233776","phase":"PHASE2","title":"Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-08-21","conditions":["Multiple Myeloma"],"enrollment":9,"completionDate":"2020-04-02"},{"nctId":"NCT04834388","phase":"PHASE2","title":"Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-08-10","conditions":["Intracerebral Hemorrhage"],"enrollment":75,"completionDate":"2025-12"},{"nctId":"NCT04018755","phase":"PHASE1,PHASE2","title":"Open-label Study of Anakinra in MPS III","status":"COMPLETED","sponsor":"Lynda E Polgreen","startDate":"2020-01-30","conditions":["Mucopolysaccharidosis III"],"enrollment":24,"completionDate":"2023-03-08"},{"nctId":"NCT03932344","phase":"","title":"Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2019-04-10","conditions":["Still Disease, Juvenile Onset"],"enrollment":306,"completionDate":"2019-08-31"},{"nctId":"NCT05280340","phase":"PHASE1,PHASE2","title":"Anakinra for Preterm Infants Pilot","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash Medical Centre","startDate":"2022-02-15","conditions":["Prematurity; Extreme","Inflammation"],"enrollment":25,"completionDate":"2025-03"},{"nctId":"NCT02780583","phase":"PHASE1","title":"Treatment of Macrophage Activation Syndrome (MAS) With Anakinra","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2016-05-15","conditions":["Macrophage Activation Syndrome"],"enrollment":9,"completionDate":"2024-04-30"},{"nctId":"NCT05785442","phase":"PHASE2","title":"Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2023-03-06","conditions":["Community-acquired Pneumonia","Hospital-acquired Pneumonia"],"enrollment":60,"completionDate":"2024-06-28"},{"nctId":"NCT03182426","phase":"PHASE1,PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":["Diabetes Mellitus, Type 1"],"enrollment":22,"completionDate":"2024-07-15"},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":["Community-acquired Pneumonia, Influenza, COVID-19"],"enrollment":20000,"completionDate":"2028-02"},{"nctId":"NCT05925790","phase":"","title":"Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels","status":"RECRUITING","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2023-07-01","conditions":["Pericarditis"],"enrollment":146,"completionDate":"2025-12-20"},{"nctId":"NCT03430011","phase":"PHASE1,PHASE2","title":"Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-02-01","conditions":["Multiple Myeloma"],"enrollment":165,"completionDate":"2023-03-30"},{"nctId":"NCT06071156","phase":"NA","title":"Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis","status":"RECRUITING","sponsor":"Azienda Ospedaliero, Universitaria Ospedali Riuniti","startDate":"2018-01-01","conditions":["Recurrent Pericarditis"],"enrollment":20,"completionDate":"2025-01-31"},{"nctId":"NCT01705756","phase":"PHASE3","title":"Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2012-11","conditions":["Familial Mediterranean Fever"],"enrollment":25,"completionDate":"2015-06"},{"nctId":"NCT06311448","phase":"","title":"Personalized Targeted Immunomodulation in COVID-19 ARDS","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2020-03-02","conditions":["COVID-19 Acute Respiratory Distress Syndrome"],"enrollment":164,"completionDate":"2022-02-01"},{"nctId":"NCT03018834","phase":"PHASE2,PHASE3","title":"Anakinra Versus Placebo for the Treatment of Acute MyocarditIS","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-30","conditions":["Acute Myocarditis"],"enrollment":120,"completionDate":"2022-05-30"},{"nctId":"NCT02179853","phase":"PHASE1,PHASE2","title":"Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-11","conditions":["Kawasaki Disease"],"enrollment":22,"completionDate":"2022-12"},{"nctId":"NCT04656184","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-20","conditions":["Kawasaki Disease"],"enrollment":84,"completionDate":"2027-03"},{"nctId":"NCT01277315","phase":"PHASE2","title":"Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-02","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":20,"completionDate":"2012-06"},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":["Severe Acute Respiratory Syndrome"],"enrollment":70000,"completionDate":"2036-06-30"},{"nctId":"NCT05074485","phase":"PHASE1","title":"Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience","status":"RECRUITING","sponsor":"Alan Prossin","startDate":"2021-07-19","conditions":["Pain"],"enrollment":70,"completionDate":"2026-05-07"},{"nctId":"NCT03249207","phase":"PHASE3","title":"SC IL-1Ra in SAH - Phase III Trial (SCIL)","status":"UNKNOWN","sponsor":"University of Manchester","startDate":"2018-10-11","conditions":["Subarachnoid Hemorrhage"],"enrollment":612,"completionDate":"2024-09"},{"nctId":"NCT02090101","phase":"PHASE2","title":"Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2014-10-10","conditions":["Metastatic Colorectal Cancer"],"enrollment":32,"completionDate":"2017-05-15"},{"nctId":"NCT04362111","phase":"PHASE3","title":"Early Treatment of Cytokine Storm Syndrome in Covid-19","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-01","conditions":["Cytokine Storm","COVID-19"],"enrollment":32,"completionDate":"2023-06-01"},{"nctId":"NCT04227275","phase":"PHASE1","title":"A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Tceleron Therapeutics, Inc.","startDate":"2019-11-22","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":16,"completionDate":"2022-11-07"},{"nctId":"NCT04357366","phase":"PHASE2","title":"suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2020-04-15","conditions":["COVID-19","Virus Diseases","Corona Virus Infection","Lower Respiratory Tract Infection Viral"],"enrollment":1000,"completionDate":"2022-04-15"},{"nctId":"NCT04544813","phase":"PHASE1","title":"A Study of JNJ-77474462 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-13","conditions":["Healthy"],"enrollment":78,"completionDate":"2021-05-30"},{"nctId":"NCT05914454","phase":"PHASE2","title":"Efficacy and Safety of Anakinra in Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2023-05-19","conditions":["Acute Respiratory Distress Syndrome"],"enrollment":36,"completionDate":"2025-09-19"},{"nctId":"NCT04594356","phase":"","title":"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist","status":"COMPLETED","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2020-11-19","conditions":["Covid19"],"enrollment":120,"completionDate":"2023-04-26"},{"nctId":"NCT05805930","phase":"PHASE3","title":"Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children","status":"NOT_YET_RECRUITING","sponsor":"Istituto Giannina Gaslini","startDate":"2023-06-01","conditions":["Pericarditis"],"enrollment":48,"completionDate":"2026-05-31"},{"nctId":"NCT04330638","phase":"PHASE3","title":"Treatment of COVID-19 Patients With Anti-interleukin Drugs","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-04-03","conditions":["COVID-19"],"enrollment":342,"completionDate":"2021-05-21"},{"nctId":"NCT03141983","phase":"PHASE2","title":"Anti-Cytokine Therapy for Hemodialysis InflammatION","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-12-15","conditions":["End-Stage Renal Disease"],"enrollment":80,"completionDate":"2021-09-02"},{"nctId":"NCT00214851","phase":"PHASE1","title":"The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2005-09","conditions":["Familial Cold Urticaria"],"enrollment":8,"completionDate":"2005-12"},{"nctId":"NCT04680949","phase":"PHASE3","title":"suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2020-12-23","conditions":["Covid19"],"enrollment":606,"completionDate":"2022-02-06"},{"nctId":"NCT04643678","phase":"PHASE2,PHASE3","title":"Anakinra in the Management of COVID-19 Infection","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-10-30","conditions":["Covid19","Pneumonia","Cytokine Release Syndrome","Corona Virus Infection","Viral Infection"],"enrollment":80,"completionDate":"2021-04-30"},{"nctId":"NCT05419206","phase":"","title":"The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients","status":"COMPLETED","sponsor":"Ramazan Gozukucuk","startDate":"2020-03-15","conditions":["COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality"],"enrollment":167,"completionDate":"2022-05-30"},{"nctId":"NCT04821414","phase":"","title":"Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2022-09-01","conditions":["Critical Illness","Sepsis, Severe"],"enrollment":0,"completionDate":"2024-12-31"},{"nctId":"NCT04035109","phase":"PHASE1,PHASE2","title":"Anakinra as a Rescue Treatment for Allergic Inflammation","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-12-16","conditions":["Asthma, Allergic"],"enrollment":0,"completionDate":"2023-10"},{"nctId":"NCT02790723","phase":"PHASE1","title":"Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-06-05","conditions":["Osteoarthritis, Knee"],"enrollment":9,"completionDate":"2022-03-17"},{"nctId":"NCT02578394","phase":"PHASE2,PHASE3","title":"Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study","status":"COMPLETED","sponsor":"Mid and South Essex NHS Foundation Trust","startDate":"2016-04","conditions":["Gout","Chronic Kidney Diseases"],"enrollment":21,"completionDate":"2022-01-26"},{"nctId":"NCT04374539","phase":"PHASE2","title":"Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2020-04-29","conditions":["Coronavirus"],"enrollment":36,"completionDate":"2021-06-29"}],"_emaApprovals":[{"date":"2002-03-08","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Kineret"}]},"crossReferences":{"NUI":"N0000179382","MMSL":"16200","NDDF":"009431","UNII":"9013DUQ28K","VUID":"4021281","VANDF":"4021281","INN_ID":"7137","RXNORM":"352734","UMLSCUI":"C0245109","chemblId":"CHEMBL1201570","ChEMBL_ID":"CHEMBL1201570","KEGG_DRUG":"D02934","DRUGBANK_ID":"DB00026","PUBCHEM_CID":"90470007","SNOMEDCT_US":"385549000","IUPHAR_LIGAND_ID":"6972","MESH_DESCRIPTOR_UI":"D053590"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Swedish Orphan Biovitrum AB (publ)","brandName":"Kineret","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2001-","companyName":"Biovitrum Ab","relationship":"Original Developer"}],"publicationCount":107,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L04AC03","allCodes":["L04AC03"]},"biosimilarFilings":[],"originalDeveloper":"Biovitrum Ab","recentPublications":[{"date":"2026 Feb 25","pmid":"41739653","title":"Therapeutic Approaches to Treat SARS-CoV-2.","journal":"ChemMedChem"},{"date":"2006","pmid":"30000931","title":"Anakinra.","journal":""},{"date":"2025","pmid":"41166331","title":"Kineret: Israel's Largest Hospital Network Transformed into the OMOP common data model for collaborative research.","journal":"PloS one"},{"date":"2025 Sep","pmid":"39557607","title":"Interleukin-1 type 1 receptor blockade attenuates the exaggerated exercise pressor reflex in male UC Davis type 2 diabetic mellitus rats.","journal":"The Journal of physiology"},{"date":"2024","pmid":"39355382","title":"Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis.","journal":"International journal of women's health"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Biovitrum Ab","companyId":"biovitrum-ab","modality":"Small molecule","firstApprovalDate":"2001","aiSummary":"","enrichmentLevel":3,"visitCount":5,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":53,"withResults":15},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:15.786042+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}